New Approaches to Myelodysplastic Syndrome Treatment

Bazinet, Alexandre; Bravo, Guillermo Montalbán

doi:10.1007/s11864-022-00965-1

Cited by 19 publications

(9 citation statements)

References 106 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…More recently, the oral Bcl‐2 inhibitor venetoclax, the anti‐CD47 monoclonal antibody magrolimab, and the anti‐TIM‐3 monoclonal antibody sabatolimab have shown promise in single‐arm studies of frontline MDS or MDS after HMA failure. Preliminary data from these ongoing studies have been summarized by others 46 . These agents are now being evaluated in ongoing registrational randomized clinical trials, and the results from these studies are eagerly awaited.…”

Section: Novel Hma‐based Strategies In Mds and Amlmentioning

confidence: 99%

See 1 more Smart Citation

Hypomethylating agents for the treatment of myelodysplastic syndromes and acute myeloid leukemia: Past discoveries and future directions

Short

Kantarjian

2022

American J Hematol

View full text Add to dashboard Cite

Azacitidine and decitabine are hypomethylating agents that have dose-dependent epigenetic and cytotoxic effects and are widely used in the treatment of myelodysplastic syndromes (MDS) and acute myeloid leukemia (AML). In this review, we discuss the path to regulatory approval of azacitidine and decitabine, highlighting the substantial efforts that have been made to optimize the dosing schedule and administration of these drugs, including the development of new, oral formulations of both agents. We also review novel combination strategies that are being investigated in ongoing clinical trials for patients with MDS and AML, as well as efforts to expand the current indications of these agents.

show abstract

Section: Novel Hma‐based Strategies In Mds and Amlmentioning

confidence: 99%

“…Preliminary data from these ongoing studies have been summarized by others. 46 These agents are now being evaluated in ongoing registrational randomized clinical trials, and the results from these studies are eagerly awaited. If positive, they may represent new standards of care for patients with newly diagnosed MDS.…”

Section: Mdsmentioning

confidence: 99%

Hypomethylating agents for the treatment of myelodysplastic syndromes and acute myeloid leukemia: Past discoveries and future directions

Short

Kantarjian

2022

American J Hematol

View full text Add to dashboard Cite

show abstract

“…The severity of the disease, prognosis and type of treatment methods for patients with MDS are assessed by International Prognostic Scoring System (IPSS) and its revised version (IPSS-R) [2][3][4]. Categories based on peripheral blood cytopenias, bone marrow blast percentage, and cytogenetic alterations allow the classification of MDS patients into low-risk MDS (LR-MDS) or high-risk MDS (HR-MDS) [3]. In the treatment of patients with HR-MDS, the main challenge is prolonging survival and inhibiting progression to AML [2].…”

Section: Introductionmentioning

confidence: 99%

“…In the treatment of patients with HR-MDS, the main challenge is prolonging survival and inhibiting progression to AML [2]. The only effective method of treating patients with HR--MDS, allowing for recovery, is allogeneic stem cell transplantation (allo-HSCT) [3]. Due to the toxicity of this treatment, particularly elderly patients with comorbidities are not qualified for this treatment.…”

Section: Introductionmentioning

confidence: 99%

“…Due to the toxicity of this treatment, particularly elderly patients with comorbidities are not qualified for this treatment. Alternatives -hypomethylating drugs (HMAs), chemotherapy or other new agents such as venetoclax, CPX-351(cytarabine and daunorubicin), ATG (anti-thymocyte globulin), and immune checkpoint inhibitors (ICIs) are being investigated to improve outcomes in HR-MDS [2,3].…”

Section: Introductionmentioning

confidence: 99%

See 1 more Smart Citation

Therapeutic options in high-risk myelodysplastic syndrome

Maksymowicz

Moqbil

Machowiec

et al. 2023

Hematology in Clinical Practice

View full text Add to dashboard Cite

Myelodysplastic syndromes (MDS) constitute a heterogeneous group of diseases characterised by ineffective haematopoiesis, dysplasia and cytopenias. The treatment for high-risk MDS (HR-MDS) depends on individual factors such as the stage of the disease, age, comorbidities, and infections.Allogeneic haematopoietic stem cell transplantation (allo-HSCT) with reduced intensity conditioning has allowed more HR-MDS patients to be transplant-eligible, regardless of age. Hypomethylating agents, including azacitidine and decitabine, remain the standard of care for HR-MDS patients who are not qualified for curative allo-HSCT. Combination therapy of azacitidine with some new drugs resulted in higher response rates than azacitidine in monotherapy. Other targeted therapies are under investigation. They include HMA with different antibodies targeting immune checkpoints -programmed cell death (ligand) 1, cytotoxic T lymphocyte antigen 4, T-cell immunoglobulin mucin-3 or cluster of differentiation 47. Larger studies are necessary to confirm their efficacy in the treatment of HR-MDS.

show abstract

Myelodysplastic Syndrome

Fuchs

2024

Comprehensive Hematology and Stem Cell Research

View full text Add to dashboard Cite

New Approaches to Myelodysplastic Syndrome Treatment

Cited by 19 publications

References 106 publications

Hypomethylating agents for the treatment of myelodysplastic syndromes and acute myeloid leukemia: Past discoveries and future directions

Hypomethylating agents for the treatment of myelodysplastic syndromes and acute myeloid leukemia: Past discoveries and future directions

Therapeutic options in high-risk myelodysplastic syndrome

Myelodysplastic Syndrome

Contact Info

Product

Resources

About